» Articles » PMID: 39604705

Practical Application of Melatonin for Pancreas Disorders: Protective Roles Against Inflammation, Malignancy, and Dysfunctions

Overview
Journal Pharmacol Rep
Specialty Pharmacology
Date 2024 Nov 28
PMID 39604705
Authors
Affiliations
Soon will be listed here.
Abstract

Melatonin, a hormone primarily produced by the pineal gland, exhibits a range of physiological functions that extend beyond its well-known role in regulating circadian rhythms. This hormone influences energy metabolism, modulates insulin sensitivity, and plays a significant role in controlling sleep patterns and food intake. Notably, melatonin is also synthesized in various peripheral organs, including the gastrointestinal system and pancreas, suggesting its function as a local hormone. The presence of melatonin receptors in the pancreas underscores its relevance in pancreatic physiology. Pancreatic disorders, such as diabetes mellitus (DM), pancreatitis, and pancreatic cancer, often stem from inflammatory processes. The majority of these conditions are characterized by dysregulated immune responses and oxidative stress. Melatonin's anti-inflammatory properties are mediated through the inhibition of pro-inflammatory cytokines and the activation of antioxidant enzymes, which help to mitigate cellular damage. Furthermore, melatonin has demonstrated pro-apoptotic effects on cancer cells, promoting cell death in malignant tissues while preserving healthy cells. Thus, melatonin emerges as a multifaceted agent with significant therapeutic potential for pancreatic disorders. Its ability to reduce inflammation and oxidative stress positions it as a promising adjunct therapy for conditions such as diabetes mellitus, pancreatitis, and pancreatic cancer. By modulating immune responses and enhancing cellular resilience through antioxidant mechanisms, melatonin not only addresses the symptoms but also targets the underlying pathophysiological processes associated with these disorders. This review aims to categorize and summarize the impacts of melatonin on pancreatic functions and disorders, emphasizing its potential as a therapeutic agent for managing pancreatic dysfunctions. Future research should focus on elucidating the precise mechanisms by which melatonin exerts its protective effects on pancreatic tissues and exploring optimal dosing strategies for clinical applications. The integration of melatonin into treatment regimens may enhance existing therapies and offer new hope for individuals suffering from pancreatic dysfunctions.

Citing Articles

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Fornari Laurindo L, Simili O, Cressoni Araujo A, Landgraf Guiguer E, Direito R, Valenti V Biology (Basel). 2025; 14(2).

PMID: 40001911 PMC: 11851571. DOI: 10.3390/biology14020143.

References
1.
Parry B, Berga S, Mostofi N, Klauber M, Resnick A . Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects. J Biol Rhythms. 1997; 12(1):47-64. DOI: 10.1177/074873049701200107. View

2.
Moller M, Baeres F . The anatomy and innervation of the mammalian pineal gland. Cell Tissue Res. 2002; 309(1):139-50. DOI: 10.1007/s00441-002-0580-5. View

3.
Zawilska J, Skene D, Arendt J . Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009; 61(3):383-410. DOI: 10.1016/s1734-1140(09)70081-7. View

4.
Hosseinzadeh A, Alinaghian N, Sheibani M, Seirafianpour F, Naeini A, Mehrzadi S . Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases. Life Sci. 2024; 344:122557. DOI: 10.1016/j.lfs.2024.122557. View

5.
Bagherifard A, Hosseinzadeh A, Koosha F, Sheibani M, Karimi-Behnagh A, Reiter R . Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects. Osteoporos Int. 2023; 34(10):1677-1701. DOI: 10.1007/s00198-023-06836-1. View